The National Institutes of Health is the largest public funder of biomedical research in the United States and not a venture capital investor in the conventional sense. Through mechanisms such as the BRAIN Initiative, SBIR/STTR, and institute-specific grants, it provides non-dilutive funding across the research and translational continuum. Its role in neurotechnology is foundational rather than equity-driven.

NIH supports a vast range of neuroscience and neurotechnology work, from basic brain research through tools, devices, and translational programs. For startups, its value is in grant support, validation, milestone funding, and scientific credibility. Many neurotech companies rely on NIH-linked funding early, especially before the stage at which institutional venture capital becomes realistic.

Its primary focus is the United States, though it also supports international collaborations. For neurotech founders, NIH is often one of the most important early funding pathways, especially in research-intensive or technically difficult areas. It should be viewed as a cornerstone non-dilutive funding source rather than a substitute for venture capital.